Nemo Money has over 1 million (1M+) downloads with a high rating of 4.6 stars from thousands of reviews. Join Nemo and trade with 0% commission.Nemo Money has over 1 million (1M+) downloads with a high rating of 4.6 stars from thousands of reviews. Join Nemo and trade with 0% commission.Nemo Money has over 1 million (1M+) downloads with a high rating of 4.6 stars from thousands of reviews. Join Nemo and trade with 0% commission.Nemo Money has over 1 million (1M+) downloads with a high rating of 4.6 stars from thousands of reviews. Join Nemo and trade with 0% commission.
NvidiaVisa

Nvidia vs Visa

This page compares Nvidia and Visa, examining how each company operates, their business models, financial performance, and their position within broader market context. It outlines core differences in...

Why It's Moving

Nvidia

Nvidia surges on biotech pivot and China chip green light amid AI momentum.

  • Shocking $1B Eli Lilly collaboration taps AI into biotech drug discovery, expanding Nvidia's addressable market dramatically.
  • Green light for H200 chip exports to China revives sales prospects despite Huawei competition and past restrictions.
  • CES 2026 updates confirm Blackwell production ramp and Rubin Ultra chips for 2027, bolstering the AI chip roadmap.
Sentiment:
🐃Bullish
Visa

Visa Stock Steadies Amid Hype for Earnings as Analysts Eye Upside Potential.

  • Adjusted EPS hit $2.98 in recent quarter, edging past forecasts of $2.97 and highlighting resilient transaction volumes despite policy volatility.
  • Q1 2026 EPS estimates near $3.14 signal strong double-digit gains, fueled by value-added services, B2B payments modernization, and stablecoin opportunities.
  • Major institutions maintain Strong Buy ratings, citing Visa's inflation-linked revenue model, hefty buybacks, and edge in agentic commerce over fintech rivals.
Sentiment:
🐃Bullish

Investment Analysis

Nvidia

Nvidia

NVDA

Pros

  • NVIDIA reported a fiscal 2025 revenue of $130.5 billion, marking a 114% increase year-over-year, demonstrating strong top-line growth.
  • The company has achieved exceptional profitability with GAAP earnings per diluted share up 147% year-over-year, supported by high returns on assets and equity.
  • NVIDIA leads in AI and high-performance computing, successfully ramping production of Blackwell AI supercomputers with significant initial sales.

Considerations

  • NVIDIA's stock price experienced a steep $450 billion market value loss over three days in 2025, reflecting high volatility and market correction risks.
  • The stock exhibits notably higher price volatility compared to Visa, which may imply greater investment risk in fluctuating markets.
  • Valuation multiples such as Price/Earnings and Price/Book are considerably high, which could raise concerns about overvaluation.

Pros

  • Visa has a more stable and lower price volatility than NVIDIA, suggesting less price fluctuation risk for investors.
  • It operates a globally dominant payments network (VisaNet), providing consistent transaction volume and resilient revenue streams.
  • Visa's business model benefits from the ongoing secular shift toward electronic payments and digital transaction growth worldwide.

Considerations

  • Visa’s stock offers slower growth potential compared to NVIDIA, reflecting its mature market position in payments technology.
  • The company's performance is sensitive to global economic cycles and consumer spending trends, which can impact transaction volumes.
  • Competition from emerging fintech and digital payment platforms presents ongoing threat to Visa’s market share expansion.

Related Market Insights

Meta Platforms Stock: Why Africa's Digital Revolution Matters for Investors

Explore Africa's booming digital economy. Invest in global tech leaders like Meta, NVIDIA, & Alphabet through Nemo's thematic Neme. Access growth with fractional shares from $1.

Author avatar

Aimee Silverwood | Financial Analyst

December 8, 2025

Read Insight

When Big Pharma Stumbles, Innovation Thrives: The Sickle Cell Opportunity

Explore the investment opportunity in sickle cell gene therapy. Pfizer's setback opens doors for innovative biotech firms developing next-gen treatments for this inherited disorder.

Author avatar

Aimee Silverwood | Financial Analyst

August 17, 2025

Read Insight

The Superbug Crisis: Why Antibiotic Innovators Could Be Medicine's Next Big Winners

Explore investment opportunities in biotech firms developing next-generation antibiotics. Learn how to invest in companies fighting drug-resistant superbugs with Nemo.

Author avatar

Aimee Silverwood | Financial Analyst

August 12, 2025

Read Insight

Nvidia (NVDA) Next Earnings Date

Nvidia's next earnings date is confirmed for Wednesday, February 25, 2026, after market close. This report will cover the fourth quarter of fiscal 2026, ending in late January 2026. Investors should note this aligns with the company's historical pattern of late-February releases for Q4 results.

Visa (V) Next Earnings Date

Visa, Inc. (V) is scheduled to report its next earnings on January 29, 2026, covering the fiscal first quarter of 2026 (Q1 2026). This follows the most recent Q4 2025 results released on October 28, 2025. The announcement is set for after market close, with a conference call to follow.

Which Baskets Do They Appear In?

Meta Platforms Stock Digital Africa Ecosystem Explained

Meta Platforms Stock Digital Africa Ecosystem Explained

Africa's digital economy is expanding rapidly, creating new opportunities for growth tied to global technology leaders. This basket offers potential exposure to the US-listed companies at the heart of this transformation, from social media giants to the infrastructure that powers them.

Published: September 22, 2025

Explore Basket
Pioneering Sickle Cell Solutions

Pioneering Sickle Cell Solutions

Pfizer's recent failure in a key sickle cell disease trial highlights the urgent need for new therapies. This setback creates a significant opportunity for innovative biotech companies developing alternative treatments, including potentially curative gene therapies.

Published: August 17, 2025

Explore Basket
Next-Generation Antibiotic Innovators

Next-Generation Antibiotic Innovators

With the FDA granting priority review to GSK's new oral antibiotic for gonorrhea, a new front has opened in the fight against drug-resistant bacteria. This theme focuses on the biotechnology companies developing the next generation of antibiotics to address this critical and growing public health need.

Published: August 12, 2025

Explore Basket

Buy NVDA or V in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Comparisons

NvidiaMastercard

Nvidia vs Mastercard

Nvidia vs Mastercard: stock comparison

NvidiaTSMC

Nvidia vs TSMC

Nvidia vs TSMC: a concise comparison

NvidiaPalantir

Nvidia vs Palantir

Nvidia vs Palantir: stock comparison

Frequently asked questions